Novartis' Alcon receives FDA approval for AcrySof IQ ReSTOR
Alcon, a division of Novartis, has received approval from the US Food and Drug Administration for its AcrySof IQ ReSTOR +3.0D Multifocal Toric Intraocular Lens. The new IOL is designed to address presbyopia and pre-existing corneal astigmatism at the time of cataract surgery in adult patients who desire good near, intermediate and distance vision with an increased potential for spectacle independence. The product is already commercially available in the European Union, Australia, Canada, and many countries in Central and South America and Asia. "The AcrySof IQ ReSTOR +3.0D Multifocal Toric IOL is an important addition to our market-leading IOL portfolio, and broadens our offering of presbyopia- and astigmatism-correcting lenses to meet the different visual needs of patients," said Sergio Duplan, Alcon Region President for North America. "We are committed to delivering ongoing innovation that enables surgeons to provide the best possible outcome for their patients."